Feb 18th 2013 - Edison Investment Research today published a report on quickview entitled "Data To Drive A Deal". In summary, the report says:
Data from five controlled trials of MolMed’s selective vascular targeting agent NGR-hTNF are due to be announced during 2013, which could trigger a partnership and help determine future Phase III development in solid tumours. A partnership is key to unlocking NGR-hTNF’s value and is in turn central to MolMed’s investment case. If Phase III data due in H2 in the initial indication of mesothelioma are positive, NGR-hTNF could be filed shortly thereafter. MolMed is also planning to file TK for EU conditional approval in high-risk leukaemia during 2013.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »